Tyra Biosciences, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Tyra Biosciences, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($29.87M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($28.10M) | Aug 14, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($28.10M) | Nov 5, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($28.15M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($28.15M) | May 8, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($28.15M) | Nov 5, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($24.02M) | Nov 5, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($18.70M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($18.70M) | Aug 14, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($18.19M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($18.19M) | May 8, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($18.19M) | Nov 5, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($21.15M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($13.27M) | Aug 7, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($13.27M) | Nov 7, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($11.88M) | Nov 7, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($11.88M) | May 9, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($11.88M) | Aug 7, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($12.51M) | Nov 7, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($15.10M) | Nov 7, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($32.94M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($31.45M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($31.85M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($28.60M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($23.53M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($22.32M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($23.96M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($16.01M) | Aug 7, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($14.33M) | May 9, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($13.65M) | Nov 7, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($15.43M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($14.83M) | May 4, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($6.64M) | Nov 3, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($5.51M) | Aug 4, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($4.21M) | May 5, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($2.33M) | Nov 3, 2021 |